Statewide Availability of Buprenorphine/Naloxone in Acute Care Hospitals.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 33758118.
- Also identified by DOI 10.1097/ADM.0000000000000833.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Evaluate the availability of buprenorphine/naloxone for inpatients with opioid use disorder in a state's acute care hospitals. An audit study of all acute care hospitals in New Mexico was performed. Hospitals were surveyed on the availability of buprenorphine/naloxone on their inpatient formularies and their ability to obtain buprenorphine/naloxone within 1 day should a patient need it. Of the surveyed hospitals, 45.5% did not have buprenorphine/naloxone on their inpatient formularies. Of the 26 counties in New Mexico with acute care hospitals, 10 did not have buprenorphine/naloxone available for inpatients. Three of these counties have drug overdose death rates equal to or higher than the state average. In 1 predominately rural state with an opioid overdose death rate higher than the national average, approximately half of acute care hospitals had buprenorphine/naloxone available to patients on their inpatient formulary. Efforts to increase buprenorphine/naloxone availability in hospitals are needed, particularly in rural areas where there may not be other locations to access treatment for opioid use disorder.
Medical subject headings
- Buprenorphine
- Drug Overdose
- Opiate Overdose
- Opioid-Related Disorders